, Volume 181, Issue 2, pp 401–406 | Cite as

Decreased striatal dopamine transporter binding assessed with [123I] FP-CIT in first-episode schizophrenic patients with and without short-term antipsychotic-induced parkinsonism

  • Jose J. MateosEmail author
  • Francisco Lomeña
  • Eduardo Parellada
  • Mireia Font
  • Emili Fernandez
  • Javier Pavia
  • Alberto Prats
  • Francisca Pons
  • Miquel Bernardo
Original Investigation



Drug-induced parkinsonism (DIP) is one of the main causes of treatment drop-out in schizophrenic patients causing a high incidence of relapse that leads patients to a bad clinical prognosis. The dopaminergic nigrostriatal pathway is involved in the movement control, so the study of the dopamine transporter (DAT) could be of great value to determine its implication in the appearance of DIP.


The goal of the study is to determine the striatal DAT binding assessed with [123I] FP-CIT SPECT in first-episode neuroleptic-naive schizophrenic in-patients with DIP after short-term antipsychotic treatment.


The [123I] FP-CIT binding ratios of ten schizophrenic in-patients who developed DIP during the first 4-week period of risperidone treatment (6±2 mg/day) were compared with ten schizophrenic in-patients treated with the same doses of risperidone and who do not developed DIP and with ten age-matched healthy subjects. Quantitative analyses of SPECTs were performed using regions of interest located in caudate, putamen and occipital cortex. Parkinsonism was assessed by the Simpson–Angus Scale and the psychopathological status by the Clinical General Impression and Positive and Negative Syndrome Scales.


Whole striatal [123I] FP-CIT binding ratios were significantly lower in patients with and without DIP than in healthy subjects (p<0.001). This was also observed in whole putamen (p<0.001) and caudate nucleus (p<0.001). Females showed higher whole striatal [123I] FP-CIT binding ratios than males (p<0.05). No differences in psychopathological scales were observed between patients with and without DIP.


Our first-episode schizophrenic patients with and without DIP after short-term risperidone treatment have a decreased striatal DAT binding assessed with [123I] FP-CIT. This alteration could be related to the schizophrenic disease or may be secondary to the antipsychotic treatment.


Schizophrenia Drug-induced parkinsonism Dopamine transporter [123I] FP-CIT SPECT 



Grants from Hospital Clinic of Barcelona (Premi Fi de Residencia 2001), Marató TV3 (Enfermedades Psiquiátricas Graves; 2001), Fondo de Investigación Sanitaria of the Spanish Ministerio de Sanidad y Consumo (contract no. PI020485) and Amersham Health are gratefully acknowledged. Thanks to Mr. J Lara, Ph.D., for his English editorial assistance and Mr. L Jover, Ph.D., for his statistical assistance.


  1. American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders (4th ed). Washington, USAGoogle Scholar
  2. Bleuler E (1950) Dementia praecox or the group of schizophrenias. International University Press, New YorkGoogle Scholar
  3. Booij J, Tissingh G, Winogrodzca A, Van Royen EA (1999) Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism. Eur J Nucl Med 26:171–182CrossRefPubMedGoogle Scholar
  4. Burn DJ, Brooks DJ (1993) Nigral dysfunction in drug-induced parkinsonism: an 18F-DOPA PET study. Neurology 43:552–556PubMedGoogle Scholar
  5. Caliguri M, Lohr J, Jeste D (1993) Parkinsonism in neuroleptic-naive schizophrenic patients. Am J Psychiatry 150:1343–1348PubMedGoogle Scholar
  6. Catafau A, Tolosa E (2004) Impact of dopamine transporter SPECT using 123I-ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes. Mov Disord 19:1175–1182CrossRefPubMedGoogle Scholar
  7. Corrigan PW, Liberman RP, Engel JD (1990) From noncompliance to collaboration in the treatment of schizophrenia. Hosp Community Psychiatry 41:1203–1211PubMedGoogle Scholar
  8. Ernst M, Zametkin AJ, Matochik JA, Jons PH, Cohen RM (1998) DOPA decarboxylase activity in attention deficit hyperactivity disorder adults. A [fluorine-18]fluorodopa positron emission tomography study. J Neurosci 18:5901–5907PubMedGoogle Scholar
  9. First MB, Spitzer RL, Williams JBW, Gibbon M (1994) Structured clinical interview for DSM-IV—patients edition (SCID-P). American Psychiatric Press, Washington, DCGoogle Scholar
  10. Gordon I, Weizman R, Rehavi M (1996) Modulatory effect of agents active in the presynaptic dopaminergic system on the striatal dopamine transporter. Eur J Pharmacol 298:27–30CrossRefPubMedGoogle Scholar
  11. Guy W (1976) Early clinical drug evaluation unit (ECDEU), National Institute of Mental Health 76:338. Rockville, USAGoogle Scholar
  12. Jibson MD, Tandon R (1998) New atypical antipsychotic medications. J Psychiatry Res 32:215–228CrossRefGoogle Scholar
  13. Kay SR, Fisbein S, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:262–273Google Scholar
  14. Kraeplin E (1919) Dementia praecox and paraphrenia. University of Edinburgh, EdinburghGoogle Scholar
  15. Laakso A, Vilkman H, Alakare B, Haaparanta M, Bergman J, Solin O, Peurasaari J, Räkköläinen V, Syvälahti E, Hietala J (2000) Striatal dopamine transporter binding in neuroleptic naïve patients with schizophrenia studied with PET. Am J Psychiatry 157:269–271CrossRefPubMedGoogle Scholar
  16. Laakso A, Bergman J, Haaparanta M, Vilkman H, Solin O, Sivälahti E, Hietala J (2001) Decreased striatal dopamine transporter binding in vivo in chronic schizophrenia. Schizophr Res 52:115–120CrossRefPubMedGoogle Scholar
  17. Laruelle M, Abi-Dargham A, Van Dyck C, Gil R, D’Souza D, Krystal J, Seibyl J, Baldwin R, Innis R (2000) Dopamine and serotonin transporter in patients with schizophrenia: an imaging study with 123I-βCIT. Biol Psychiatry 47:371–379CrossRefPubMedGoogle Scholar
  18. Lavalaye J, Booij J, Reneman L, Habraken J, Van Royen E (2000) Effect of age and gender on dopamine transporter imaging with [123I] FP-CIT SPECT in healthy volunteers. Eur J Nucl Med 27:867–869CrossRefPubMedGoogle Scholar
  19. Lavalaye J, Linszen DH, Booij J, Dingemans PM, Reneman L, Habraken J, Gersons B, Van Royen E (2001) Dopamine transporter density in young patients with schizophrenia assessed with [123I] FP-CIT SPECT. Schizophr Res 47:59–67CrossRefPubMedGoogle Scholar
  20. Lieberman JA, Kinon BL, Loebel AD (1990) Dopaminergic mechanisms in idiopathic and drug-induced psychoses. Schizophr Bull 16:97–110PubMedGoogle Scholar
  21. McCreadie RG, Thara R, Kamath D, Padmavati R, Latha S, Mathrubootham N, Menon S (1996) Abnormal movements in never medicated Indian patients with schizophrenia. Br J Psychiatry 168:221–226PubMedCrossRefGoogle Scholar
  22. McCreadie R, Padmavati R, Thara R, Srinivasan TN (2002) Spontaneous dyskinesia and parkinsonism in never-medicated, chronically ill patients with schizophrenia: 18-month follow-up. Br J Psychiatry 181:135–137CrossRefPubMedGoogle Scholar
  23. Miller LG, Jankovic J (1990) Neuroleptic approach to drug-induced movement disorders: a study of 125 patients. South Med J 83:525–532PubMedGoogle Scholar
  24. Peralta V, Cuesta M, Campos MS (2002) Sintomas extrapiramidales en pacientes esquizofrénicos nunca tratados con neurolépticos. Aula Méd Psiquiátr 4:269–280Google Scholar
  25. Rajput AH, Rozdilsky B, Hornykiewicz O, Shannak K, Lee T, Seeman P (1982) Reversible drug-induced parkinsonism. Clinicopathologic study of two cases. Arch Neurol 10:644–646Google Scholar
  26. Reader TA, Ase AR, Huang N, Hebert C, Van Gelder NM (1998) Neuroleptics and dopamine transporters. Neurochem Res 23:73–80CrossRefPubMedGoogle Scholar
  27. Richelson E, Pfenning M (1984) Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: most antidepressants selectively block norepinephrine uptake. Eur J Pharmacol 104:277–286CrossRefPubMedGoogle Scholar
  28. Rivest R, Falardeau P, Di Paolo T (1995) Brain dopamine transporter: gender differences and effect of chronic haloperidol. Brain Res 692:269–272CrossRefPubMedGoogle Scholar
  29. Seeman MV (1997) Psychopathology in women and men: focus on female hormones. Am J Psychiatry 154:1641–1647PubMedGoogle Scholar
  30. Simpson GM, Angus JW (1970) A rating scale for extra-pyramidal side effects. Acta Psychiatr Scand, Suppl 212:11–19CrossRefGoogle Scholar
  31. Sjoholm H, Bratlid T, Sundsfjord J (2004) 123I β-CIT SPECT demonstrates increased presynaptic dopamine transporter binding sites in basal ganglia in vivo in schizophrenia. Psychopharmacology 173:27–31CrossRefPubMedGoogle Scholar
  32. Tatsch K, Scherer J, Linke R, Kerner M, Hahn K (1999) Decrease of dopamine transporter binding in neuroleptic-free schizophrenic patients assessed with IPT-SPECT (abstr.) J Nucl Med 40:31Google Scholar
  33. Tissingh G, Booij J, Bergmans P, Winogrodzka A, Janssen AG, Van Royen EA, Stoof JC, Wolters E (1998) Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-ebeta-(4-iodophenyl)-tropane SPECT in healthy controls and early-stage, drug-naïve Parkinson’s disease. J Nucl Med 39:1143–1148PubMedGoogle Scholar
  34. Valchar M, Hanbauer I (1993) Comparison of 3HWIN 35,428 binding, a marker for dopamine transporter, in embryonic mesencephalic neuronal cultures with striatal membranes of adult rats. J Neurochem 60:469–476PubMedCrossRefGoogle Scholar
  35. Vander T, Kilbourn M, Desmond T, Kuhl D, Frey K (1995) The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur J Pharmacol 294:577–583CrossRefPubMedGoogle Scholar
  36. Verhoeff NPLG (1999) Radiotracers imaging of dopaminergic transmission in neuropsychiatric disorders. Psychopharmacology 147:217–249CrossRefPubMedGoogle Scholar
  37. Walker Z, Costa DC, Walker RWH, Shaw K, Gacinovic S, Stevens T, Livingston G, Ince P, McKeith IG, Katona CLE (2002) Differentiation of dementia with Lewy bodies from Alzheimer’s disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry 73:134–140CrossRefPubMedGoogle Scholar
  38. Wolff A, O’Driscoll G (1999) Motor deficits and schizophrenia: the evidence from neuroleptic-naïve patients and populations at risk. J Psychiatry Neurosci 24:304–314PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • Jose J. Mateos
    • 1
    Email author
  • Francisco Lomeña
    • 1
  • Eduardo Parellada
    • 2
  • Mireia Font
    • 2
  • Emili Fernandez
    • 2
  • Javier Pavia
    • 1
  • Alberto Prats
    • 3
  • Francisca Pons
    • 1
  • Miquel Bernardo
    • 2
  1. 1.Nuclear Medicine Department, Hospital Clinic of BarcelonaUniversity of BarcelonaBarcelonaSpain
  2. 2.Psychiatry DepartmentHospital Clinic of BarcelonaBarcelonaSpain
  3. 3.Anatomy DepartmentUniversity of BarcelonaBarcelonaSpain

Personalised recommendations